Investing.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%,此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。 这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据,患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中,89.5%描述...
Source LinkInvesting.com -- Incannex Healthcare Inc. (NASDAQ:IXHL)股价周五上涨10%,此前该公司发布了其阻塞性睡眠呼吸暂停(OSA)治疗药物IHL-42X的积极第二阶段试验结果。 这家临床阶段制药公司报告了其RePOSA第二阶段试验的令人信服的有效性数据,患者退出访谈显示57.6%的参与者感受到他们的OSA状况有所改善。在报告获益的患者中,89.5%描述...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.